Navigation Links
According to Surveyed U.S. Oncologists, Perjeta is Prescribed to Over One-Third of First-Line Advanced/Metastatic HER2-Positive, HR-Negative Breast Cancer Patients
Date:12/19/2013

EXTON, Pa., Dec. 19, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, according to oncologists surveyed in Q4 2013, Roche/Genentech's Perjeta in combination with Roche/Genentech's Herceptin and docetaxel is prescribed to over one-third of first-line HER2-positive, hormone-receptor (HR)-negative advanced/metastatic breast cancer patients. Findings in the same HER2-positive, HR-negative population reveal that Roche/Genentech's Kadcyla has become the patient-share leader in the second-line setting. Surveyed oncologists also reported that Novartis's Afinitor holds modest patient shares in the second- and third-line settings for HR-positive, HER2-negative breast cancer.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO)

The TreatmentTrends® Advanced/Metastatic Breast Cancer (US) Q3 2013  report, in which 100 medical oncologists were surveyed about their current and expected treatment practices for breast cancer, also finds that out-of-pocket costs to patients is one of the top three main obstacles that prevent surveyed physicians from prescribing currently available premium-priced treatments for advanced/metastatic breast cancer. Notably, other key obstacles to prescribing were safety/tolerability and managed care/prior authorization problems.

"The market entry of several novel targeted agents with strong efficacy data in the last 18 months is changing previous treatment paradigms," said Decision Resources Group Principal Business Insights Analyst Amy Duval, M.Res. "These new market entries command premium prices, and some cost-related issues are obstacles to prescribing for surveyed oncologists."

TreatmentTrends® Advanced/Metastatic Breast Cancer is a syndicated report designed to provide a view of the current and future management of breast cancer based on primary research fielded with 100 medical oncologists in the United States. The report evaluates treatment and diagnosis patterns of the disease and physician opinions on possible future therapy options. BioTrends Oncology is also covering the launch of Perjeta and Kadcyla through its LaunchTrends® studies.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Shingles Vaccine is Safe, According to New Study
2. Vaccines are dangerous, according to Saynotovaccines.org - Get all the facts!
3. Vaginal Mesh Lawsuits Pick Up Momentum, According To Pulaski & Middleman, LLC
4. Latest Drug Sales Data: Loss of Patent Protection Has Significant Effect, According to Drugs.com
5. Over 123 Million Medical Device Units Recalled in Second Quarter of 2012, Reaching an Eight-Quarter High, According to the ExpertRECALL Index
6. Epigenomics Presents Significant Opportunities for Investment and Product Development, According to New Biotech Market Research
7. European Market for Dental Instruments Surpasses $652 Million, According to New Market Research
8. According to New Survey, Most Men are Not Proactive about Their Health Despite the Desire to Live Long Lives
9. Food Recalls Rise to Four a Day in Third Quarter, Reaching Highest Level of Activity in Eight Quarters, According to the ExpertRECALL Index
10. Affluence, an Aging Population, and Anticipated Rx-to-OTC Switches Boost a Healthy $32 Billion OTC Market in China, According to Kline
11. Life Sciences Venture Capital Funding Drops 14% During 2012, According To The MoneyTree Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... , May 27, 2016 ... instances of hypertension is driving ambulatory blood pressure monitoring ... their elasticity and their ability to respond to different ... This condition can lead to various cardiovascular disorders such ... vascular disease. These diseases are growing in prevalence each ...
(Date:5/27/2016)... 27, 2016 The healthcare sector ... insurance companies all falling under its umbrella.  A rather ... not often talked about, these healthcare companies are still ... is by far the largest consumer of ... Corp. (OTC: ADMD), Nutranomics Inc. (OTC: NNRX), KollagenX Corp. ...
(Date:5/26/2016)... Tenn. , May 26, 2016 /PRNewswire/ ... of software and analytics, network solutions and ... today announced it entered into a strategic ... provider of outpatient software solutions and revenue ... centers, specialty hospitals and rehabilitation clinics to ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... 2016 , ... The Global Wellness Summit (GWS), an annual conference ... of wellness, travel, spa and beauty in Europe. The organization asked its partner experts ... economists and researchers - to forecast where wellness is headed in Europe. Predictions range ...
(Date:5/31/2016)... ... May 31, 2016 , ... The Orthopaedic Research and Education Foundation (OREF) is ... G. Lewallen, MD, began his term as president in March, succeeding John J. Callaghan, ... OREF’s new president-elect. Richard F. Kyle, MD, will serve as chair, corporate development, succeeding ...
(Date:5/31/2016)... ... May 31, 2016 , ... In a recent interview on The Greenburgh ... New Rochelle, NY-based WVOX (1460 AM), leading medical insurance advocate Adria Goldman ... country’s “modern medical money maelstrom.” , During the interview with Mr. Feiner that ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... ... to apply information technology solutions to the healthcare industry, The University of Scranton ... program offers an accelerated path to a career in rapidly growing field of ...
(Date:5/30/2016)... (PRWEB) , ... May 30, 2016 , ... ... to use inside of FCPX," said Christina Austin - CEO of Pixel Film ... for use within Final Cut Pro X. Choose from abstract transitions to more ...
Breaking Medicine News(10 mins):